smartdyelivery

est. 2014

Our Vision

" Magical spheres " for the therapy of diseases

Our Vision

„We must learn to create magical spheres that ... only hit the pathogens.”

Paul Ehrlich 1854-1915

With tailor-made nanocarriers, we will set new standards for the targeted, efficient and low-risk use of active pharmaceutical ingredients and other highly potent substances for medical and life science applications.

NEWS

June 16, 2020

INVESTOR DAYS THURINGIA - DIGITAL EDITION FROM 16-17 JUNE: This year everything is different and so Thuringia Investor Days will be presented in a new digital format. Under the theme "Playing Changes", innovative start-ups and growth companies can present themselves to potential investors and business angels from home in live pitches and with a virtual exhibition booth. SmartDyeLivery will also be part of the event again and is looking forward to two exciting virtual days!

May 19, 2020

JOINT PUBLICATION WITH RESEARCHERS FROM THE UNIVERSITY OF JENA: The close cooperation with scientists from the Institute of Organic Chemistry and Macromolecular Chemistry (IOMC) has now resulted in a shared high-ranking publication in the journal Analytical Chemistry. In this paper, young scientist Gizem Cinar and colleagues present a new method for the quantitative investigation of physicochemical properties of nanoparticles, among other things, in human blood serum. The experimentally developed methods can be used for future comprehensive quality assurance in nanomedical applications.

May 06, 2020

THE THURINGIAN PHARMA COMMUNITY IS ONLINE! With its joint Internet presence, ith its joint Internet presence, the Thuringian Pharma Community is now showing the unique close cooperation between science, industry and medicine to the outside world. Founded in 2016, the initiative has set itself the goal of giving Thuringia a lasting and unmistakable visibility as a pharmaceutical location. The community now comprises 20 partners, including companies of all sizes, research institutes, hospitals and state institutions. SmartDyeLivery has also joined the community in 2019 and has already been able to win valuable cooperation.

DEVELOPMENT OF NEW THERAPY OPTIONS

In a first field of application we focus on the targeted transport of active substances in liver cells. We are thus creating a therapeutic option for the treatment of patients with septic cholestasis with the aim of reducing the extremely high mortality rate caused by this complication.